Making Critical Decisions in EGFR-Mutant Lung Cancers: How to Apply Evidence to Decide What to Do When the Patient is There in Front of You
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.

Disclaimer

Not an official event of the 2017 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Making Critical Decisions in EGFR-Mutant Lung Cancers: How to Apply Evidence to Decide What to Do When the Patient is There in Front of You


Friday, June 2, 2017
7:00PM-9:00PM
Dinner and registration: 6:30PM - 7:00PM

Hilton Chicago
Continental Ballroom, Lobby Level
720 S Michigan Avenue
Chicago, IL 60605

Overview:

Making Critical Decisions in EGFR-mutant Lung Cancers: How to Apply Evidence to Decide What to Do When the Patient is There in Front of You is a live symposium to be held adjunct to the annual meeting in Chicago. Targeting known oncogenic drivers, such as the epidermal growth factor receptor (EGFR), has allowed for the clinical development of strategies that improve the balance between efficacy and toxicity compared with previous standards of care in advanced forms of non–small cell lung cancers (NSCLCs). However, practice-based barriers and challenges related to tumor tissue testing remain, and these complicate the application of the most precise/optimized evidence-based strategies along the disease continuum. Several factors are key to optimize outcomes, including choosing the best initial treatment, when to rebiopsy and/or retest for molecular markers (and the method by which to do so), the decision on when to switch, what constitutes progression, selecting the best approach at the time of acquired drug resistance, mitigation of treatment-related toxicities, and the management of central nervous system metastases. These issues must all be addressed at key decision points along the disease continuum in the care of these patients. The rapid pace and sheer volume of basic science and therapeutic developments that continue to emerge in EGFR-mutant lung cancers creates knowledge and practice gaps among clinicians who strive to maintain state-of-the-art care for their patients. This dynamic, cutting-edge symposium will feature the most up-to-date approaches for the care of patients with EGFR-mutant NSCLCs, with the opportunity for interaction between the expert faculty and participants. Key topics to be addressed by faculty include:

  • Current and emerging strategies for initial therapy of patients with EGFR-mutant NSCLCs
  • How liquid biopsies can facilitate molecular assessment of acquired resistance
  • Choosing the optimal approach in patients progressing on an EGFR inhibitor
  • Leveraging local and systemic approaches to manage central nervous system metastases

The symposium will be held at the Hilton Chicago, on June 2, 2017, from 7 - 9 PM. Please join us in Chicago for expert advice on successfully navigating therapeutic decision points for patients with EGFR-mutant NSCLCs. You won’t want to miss this activity.

Target Audience:

This educational activity is directed toward medical oncologists who treat patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer will be invited to participate.

Learning Objectives:

After successful completion of this educational activity, participants should be able to:

  • Describe evolving roles for liquid biopsies as a method to overcome inherent challenges associated with tumor tissue testing and facilitate precision in therapeutic selection at critical decision points along the disease continuum in advanced NSCLC
  • Detail current and emerging strategies to personalize front-line treatment and monitor patients with advanced EGFR-mutated NSCLC
  • Explain clinical trial evidence concerning methods to address acquired resistance and progression in EGFR-mutated patients with advanced NSCLC
  • Delineate methods to manage treatment-related toxicities and central nervous system metastases in multiple lines of care for patients with advanced NSCLC


Program Chair

Mark G. Kris, MD
Attending, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY


Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
293031
Filter By